Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20346586 | 0.91 | NPC1 (0.52) | TTRABCG2TNKSPARP1NPC1 | |
| SCHEMBL20350012 | 0.90 | NPC1 (0.51) | TTRABCG2TNKSPARP1NPC1 | |
| SCHEMBL20350005 | 0.89 | NPC1 (0.56) | TTRABCG2TNKSNPC1RAB9A | |
| SCHEMBL20350099 | 0.84 | ABCG2 (0.43) | TTRABCG2TNKSNPC1RAB9A | |
| SCHEMBL490247 | 0.84 | TTR (0.68) | TTRTNKSPARP1NPC1RAB9A | |
| SCHEMBL20317216 | 0.83 | TTR (0.52) | TTRTNKSPARP1NPC1RAB9A | |
| SCHEMBL3966330 | 0.82 | CREBBP (0.56) | TTRTNKSPARP1NPC1RAB9A | |
| SCHEMBL11319698 | 0.80 | KDM4E (0.56) | TTRTNKSNPC1RAB9ACREBBP | |
| SCHEMBL18287966 | 0.80 | TNKS (0.58) | TTRTNKSPARP1NPC1RAB9A | |
| SCHEMBL29886856 | 0.80 | TNKS (0.58) | TTRTNKSPARP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185325-A1 | 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME | THESAN PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185325-A1 | 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME | THESAN PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185325-A1 | 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME | AHR, NR1H2, NR1H3 | TTR 2437/4885ABCG2 411/4885TNKS 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.